Opicapone
FDA-approved product (capsule, oral), marketed as Ongentys.
- Registered studies
- 49
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Parkinson disease
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other dopaminergic agents
- FDA pharmacologic class
- Catechol-O-Methyltransferase Inhibitor FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA49.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli31.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae24.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis59.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
49registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Opicapone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- FurazolidoneExisting use: Other antiinfectives and antiseptics91.4% AI-predicted activityagainst M. tuberculosisLab records exist49 registered studies
- TriflupromazineExisting use: Psychosis90.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- ValdecoxibExisting use: Dysmenorrhea, Osteoarthritis, Rheumatic disease and 1 more88.6% AI-predicted activityagainst M. tuberculosisLab records exist31 registered studies
- CelecoxibExisting use: Ankylosing spondylitis, Cancer, Colorectal neoplasm and 15 more87.6% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Dorzolamide HydrochlorideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma86.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- MethazolamideExisting use: Glaucoma, Open-angle glaucoma85.6% AI-predicted activityagainst M. tuberculosisLab records exist11 registered studies
- AcetazolamideExisting use: Altitude sickness, Angle-closure glaucoma, Congestive heart failure and 5 more85.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Trifluoperazine HydrochlorideExisting use: Anxiety disorder, Mental or behavioural disorder, Psychosis and 1 more84.6% AI-predicted activityagainst M. tuberculosis1 registered study
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives84.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- NitrofurazoneExisting use: Eye infection, Leishmaniasis, Trypanosomiasis84.0% AI-predicted activityagainst M. tuberculosis8 registered studies
- BrinzolamideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma83.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- ZonisamideExisting use: Epilepsy, Focal-onset seizure, Partial epilepsy and 1 more82.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/Benserazide
NCT02169895 · start 2008-09
Registered record
- Registry ID
- NCT02169895
- Conditions
- Parkinson's Disease (PD)
- Interventions
- BIA 9-1067; Placebo; Prolopa®
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2008-09
- Completion
- 2008-11
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionParkinson's Disease (PD)InterventionBIA 9-1067; Placebo; Prolopa®PhasePhase 1Registry statusCompletedComparative Bioavailability Study of BIA 9-1067 25 mg Capsules
NCT02071823 · start 2008-05
Registered record
- Registry ID
- NCT02071823
- Conditions
- Parkinson
- Interventions
- BIA 9-1067
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2008-05
- Completion
- 2008-06
- Enrolment
- 12
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionParkinsonInterventionBIA 9-1067PhasePhase 1Registry statusCompletedTolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067
NCT02071810 · start 2008-04
Registered record
- Registry ID
- NCT02071810
- Conditions
- Parkinson's Disease (PD)
- Interventions
- BIA 9-1067; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2008-04
- Completion
- 2008-09
- Enrolment
- 34
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionParkinson's Disease (PD)InterventionBIA 9-1067; PlaceboPhasePhase 1Registry statusCompletedA Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male Subjects
NCT01520727 · start 2007-10
Registered record
- Registry ID
- NCT01520727
- Conditions
- Parkinson Disease
- Interventions
- BIA 9-1067; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2007-10
- Completion
- 2009-04
- Enrolment
- 64
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionParkinson DiseaseInterventionBIA 9-1067; PlaceboPhasePhase 1Registry statusCompleted